0
Abstract: Slide Presentations |

REFINING THE CONCEPT OF HEALTHCARE-ASSOCIATED PNEUMONIA: PREDICTION RULES FOR RESISTANT PATHOGENS IN SEVERE PNEUMONIA IN THE EMERGENCY DEPARTMENT FREE TO VIEW

Matthew P. Schreiber, MD; Chee M. Chan, MD; Andrew F. Shorr, MD*
Author and Funding Information

Washington Hospital Center, Washington, DC


Chest


Chest. 2009;136(4_MeetingAbstracts):6S. doi:10.1378/chest.136.4_MeetingAbstracts.6S-f
Text Size: A A A
Published online

Abstract

PURPOSE:  Resistant organisms such as Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PA) may cause pneumonia in patients presenting to the hospital. Healthcare-associated pneumonia (HCAP) was developed to identify those with community-onset pneumonia but who may be at risk for resistant organisms (ROs). The HCAP paradigm has not been validated in critically ill subjects.

METHODS:  We retrospectively identified persons who, over a 3 yr period, presented to the hospital with pneumonia requiring mechanical ventilation. We only included persons with evidence of bacterial infection (e.g. positive lower respiratory tract cultures, blood cultures, or urinary antigen testing). We compared those with ROs (MRSA, PA, EBSL) to those with other pathogens in terms of demographics, co-morbidities, severity of illness, and risk factors for HCAP. We considered HCAP present if the patient was either immunosuppressed, undergoing hemodialysis, admitted from long-term care (LTC), or had received antibiotics in the last 30 days.

RESULTS:  The final cohort included 190 subjects (median age 61 yrs, 54% male) & ROs were seen in 32.6%. Neither demographics, severity of illness, nor most co-morbidities differed between those with ROs and persons with other pathogens. Approximately half of subjects met criteria for HCAP, & ROs were more common in HCAP (71.7% vs. 39.2%, p=0.001). The prevalence of ROs increased among patients with multiple HCAP factors. Those with ≥2 risk factors were 5.9 times more likely to have an RO (95% CI: 2.8–12.3). As a screening test for ROs, HCAP had a poor area under the receiver operating curve (0.66, 95% CI: 0.58–0.75). Logistic regression revealed 2 variables independently associated with ROs: immunosuppression (OR: 4.9, 95% CI: 2.2–10.6) & admission from LTC (OR: 2.4, 95% CI: 1.1–5.1).

CONCLUSION:  Although HCAP identifies patients at increased risk for ROs not all components of the HCAP definition contribute equally to explaining the prevalence of ROs. Refinements to the definition are warranted.

CLINICAL IMPLICATIONS:  Physicians should consider more focused utilization of broad spectrum antibiotics rather than using them in all patients with HCAP.

DISCLOSURE:  Andrew Shorr, Grant monies (from industry related sources) Astellas, GSK, J and J, Pfizer, Sanofi; Consultant fee, speaker bureau, advisory committee, etc. Astellas, BI, GSK, J and J, Medicines Co. Merck, Pfizer, Sanofi, Theravance; No Product/Research Disclosure Information

Monday, November 2, 2009

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543